Iomeprol
 | |
| Clinical data | |
|---|---|
| Trade names | Imeron, others |
| Routes of administration | Intravenous, intra-arterial |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | none |
| Elimination half-life | 109±20 min |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H22I3N3O8 |
| Molar mass | 777.089 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.[1][2][3]
It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.[2] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.[2]
The substance is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.[4]
Society and culture
Legal status
Iomeprol was approved for medical use in the United States in November 2024.[1][5]
References
- ^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216017s000,216017s000lbl.pdf
- ^ a b c Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.
- ^ Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.
- ^ Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
